2024 EHA Congress MCL Highlights

CME

Independent Conference Highlights of the 2024 EHA Congress: Spotlight on Mantle Cell Lymphoma

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: August 23, 2024

Expiration: August 22, 2025

Toby A Eyre
Toby A Eyre, MBChB, MD

Activity

Progress
1 2
Course Completed

Introduction

In this module, Toby A. Eyre, MBChB, MD, discusses key findings in the management of mantle cell lymphoma (MCL) presented at the 2024 European Hematology Association Congress (EHA 2024), including updates of novel targeted therapy treatment approaches in the first-line and relapsed/refractory (R/R) disease settings and epidemiologic studies providing important clinical practice insights and highlighting ongoing therapeutic needs in older patients with MCL.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with MCL do you provide care for in a typical month?

Which of the following findings was reported from the randomized, double-blind phase III ECHO trial of acalabrutinib plus bendamustine/rituximab (BR) compared with placebo plus BR in older patients with previously untreated MCL?

Which of the following CD3 x CD20 bispecific antibodies has shown high response rates with durable responses in patients with R/R MCL after previous BTK inhibitor treatment and is now being evaluated in an ongoing randomized phase III trial as a single agent vs investigator’s choice of therapy of either BR or lenalidomide/rituximab?

Which of the following results was reported with the combination of ibrutinib plus venetoclax from an analysis of the subgroup of patients with MCL and TP53 mutations enrolled on the SYMPATICO trial?